SUPPLEMENT MANUFACTURER DUE DILIGENCE
Choose the route that fits the product you are actually building. Start by defining the formula, target market, evidence boundary, quality requirements and commercial deliverables before selecting a manufacturing partner.
THE FIRST DECISION
A supplier comparison is useful only after the buyer has defined what must be decided, documented and delivered. The questions below distinguish a catalogue route from a scoped CDMO programme without assuming that every supplier operates in the same way.
PRIVATE LABEL ROUTE
This route can fit a brand when an existing product format, standard specifications and a conventional commercial route meet the project requirements. The buyer should still confirm what is included, documented and contractually permitted.
CDMO ROUTE
This route is appropriate when product requirements, evidence, target market, technical work or commercial deliverables need to be defined before production. The scope, responsibilities and any rights are confirmed for the specific programme.
BUYER SELECTION PROTOCOL
What is the product category, format and first target market?
Which formulation, evidence, documentation and analytical decisions are already made — and which are not?
Who owns each decision and what is the business deadline?
What must be included in the project deliverables and what requires a separate Work Order?
What does the signed agreement need to define about confidentiality, permitted use and any transfer conditions?
What evidence can the supplier provide for the specific scope rather than as a generic marketing statement?
CHOOSE THE RIGHT NEXT ROUTE
For a physician or clinic-led supplement programme that requires a defined development route.
For a bespoke programme that needs product, evidence, market and technical scoping before any quotation.
Review the current published quality systems, registrations and legal evidence before opening a confidential project discussion.
PAID DISCOVERY
Paid Discovery defines the agreed product route, evidence boundary and contracted deliverables. It does not include practical validation, external work or production unless those activities are separately scoped and prepaid.
INITIATE PAID DISCOVERYRELATED INTELLIGENCE
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.